

Pocket Guideline

for Dengue Clinical Case Management 2022 (Revised)



National Malaria Elimination & Aedes Transmitted Diseases Control Program Disease Control Division Directorate General of Health Services Mohakhali, Dhaka-1212









Pocket Guideline for Dengue Clinical Case Management 2022 (Revised)

Editorial Board

Advisor	: Prof. Dr. Abul Bashar Mohammad Khurshid Alam, Director General, DGHS	
Chief Patron	: Prof. Dr. Md. Nazmul Islam, Director, Disease Control & Line Director, CDC, DGHS	
Editor in Chief	: Prof. Quazi Tarikul Islam	
Editors	: Prof. Ahmedul Kabir	
	Prof. HAM Nazmul Ahasan	
	Prof. Md. Billal Alam	
	Prof. Md Titu Miah	
	Prof. Dr. Md. Robed Amin	
	Prof. Md. Jahangir Alam	
	Prof. Rubina Yasmin	
	Dr. Hafez Md. Nazmul Ahsan	
	Dr. Mohammad Rafiqul Islam	

Managing Editor : Dr. Md. Ekramul Haque

National Malaria Elimination & Aedes Transmitted Diseases Control Program Disease Control Division, DGHS Mohakhali, Dhaka-1212

01

New revised WHO Dengue case classification by severity

- A) Dengue without warning signs: Group A (Send home).
- B) Dengue with warning signs: Group B (Referred for in-hospital care).
- C) Severe dengue: Group C (Require emergency management).





Clinical Presentation of Dengue

- Dengue fever
- Dengue haemorrhagic fever
- Dengue shock syndrome
- Expanded dengue syndrome

Dengue fever

- Headache
- Myalgia
- Arthralgia / bone pain (break-bone fever)
- Rash
- GIT manifestations: Nausea, vomiting, diarrhea (seen in recent outbreaks)
- Haemorrhagic manifestations (mild, unusual hemorrhage)
- Leukopenia (WBC <5,000 cells/mm3) Platelet count ≤150,000 cells/mm3
- Rising Hct. 5-10%

Diagnosis:

Tourniquet test positive + WBC \leq 5,000 cells/cu.mm (positive predictive value = 83%)

Tourniquet Test

The tourniquet test is part of the new WHO case definition for Dengue. The test is a marker of capillary fragility and it can be used as a triage tool to differentiate patients with Dengue fever from other non Dengue febrile illness.

How to do a Tourniquet Test

- Take the patient's blood pressure and record it, for example, 100/70.
- Inflate the cuff to a point midway between SBP and DBP and maintain for 5 minutes. (100+70)/2= 85 mm Hg
- The pressure is released for at least one minute and the skin below the cuff is examine for petechiae. See image at right
- A finding of 10 or more petechiae in one square inch area considered positive. In DHF, the test usually gives a definite positive result when there is 20 petechiae per 1 inch with a sensitivity of more than 90%



Positive tourniquet test with greater than 10 petechiae per one square inch

06

Dengue Haemorrhagic Fever

Clinical:

- High, continuous fever 2-7 days.
- Haemorrhagic manifestations; tourniquet test positive, petechiae, epistaxis, haematemesis etc.
- Liver enlargement ±
- Shock ±

Laboratory:

- Evidence of plasma leakage; rising Hct. ≥20%, pleural effusion, ascites, hypoalbuminemia (serum albumin <3.5 gm% or <4gm% in obese patients)
- Platelet count $\leq 100,000$ cells/mm³.

Evidence of Plasma Leakage (key differentiating point between Dengue and Dengue Haemorrhagic Fever)

- Rise in Hct. : 20% (eg. In children 35→42 and in adults 40→48)
- Circulatory failure: Cold/cold clammy skin, CRFT>2 Sec, tachycardia, weak pulse, narrow pulse pressure <20, hypotension.
- Fluid accumulation Ascites/ Pleural effusions
- Albumin <3.5 gm/dl



Dengue Shock Syndrome

Clinical Signs of Dengue Shock Syndrome:

- Cool extremities, delayed capillary refill time
- Lethargy or restlessness (which may be a sign of reduced brain perfusion)
- Tachypnoea or Kussmaul's breathing
- Tachycardia, weak pulse
- Narrow pulse pressure: Pulse pressure ≤20 mmHg with increased diastolic pressure, e.g. 100/80 mmHg
- Hypotension by age, defined as systolic pressure <80 mmHg for those aged <5 years or 80 to 90 mmHg for older children and adults

Expanded Dengue Syndrome

- Unusual manifestations with severe organ involvement such as liver, kidneys, brain or heart associated with Dengue infection reported in DHF and also in DF who do not have evidence of plasma leakage.
- These unusual manifestations may be associated with co-infections, co-morbidities or complications of prolonged shock.

Investigations

- 1 to 5 days of fever : CBC, NS1 antigen, SGOT and SGPT (Not mandatory but helpful)
- After day7 : IgM and IgG Antibodies (Day 5-7 window period)
- Follow up testing may be done on 1st afebrile day, but should be done daily when DHF is suspected
- Haematocrit:

-A regular haematocrit is more important for management than the thrombocytopenia

-In severe dengue especially with shock hourly haematocrit is crucial for management

Clinical and Laboratory Criteria for Patients who can Be Treated at Home

- Able to tolerate orally well, good urine output and no history of bleeding
- Absence of warning signs
- Physical examination:
 - -Haemodynamically stable
 - -No tachypnoea or acidotic breathing.
 - -No tender liver or abdominal tenderness
 - -No bleeding manifestation
 - -No sign of third space fluid accumulation
 - -No alterations in mental state
- Investigation:
 Stable serial Hct.
- No other criteria for admission (i.e- co-morbidities, pregnancy, social factors)

Management Plan for Group-A Patient

These patients will be advised for home management

- · Advised for adequate bed rest
- Adequate fluid intake (around 2500 ml or 8-10 glasses for average-sized adults or accordingly in children, around 50ml/kg)-e.g. milk, fruit juice (caution with diabetic patients), oral rehydration solution (ORS) or barley/rice water/coconut water
- Take paracetamol (not more than 3 grams per day for adults; 10-15 mg/kg/dose, not more than 3 to 4 times in 24 hours in children)
- Tepid sponging
- These patients will be advised to avoid Acetylsalicylic acid (aspirin), Mefenamic acid, Ibuprofen or other NSAIDs, Steroids, Antibiotics
- These patients should be immediately taken to the nearest hospital in 1st afebrile day with worsening of the situation or if any warning sign is observed
- Observe urine output. If no urine output for 4–6 hours go immediately to nearby hospital

Fluid Management Plan for Group-B Patients



Guide to rate of fluid intake in Critical Phase-without shock

Rate of IV fluid for children (Fluids for adults are mentioned within brackets)

Drop Calculation : $(ml/h \div 4 = drops/min)$

40ml/hour = 10 drops/min 80ml/hour = 20 drops/min 100ml/hour = 25 drops/min 200ml /hr = 50 drops/min

Figure 1 : IV Fluid Therapy for Compensated Shock



Figure 2 : Flow Diagram for Profound Shock (Decompensated Shock)



Figure 3 : Flow Diagram for the Management of Fluid Overload



Two types of IV fluids are used in Dengue

- 1. Crystalloid (first choice)
- 2. Colloid

Indications of IV fluid in Dengue

- When the patient cannot have adequate oral fluid intake or vomiting
- When Hct continues to rise 10-20% despite oral rehydration
- · Impending shock/Shock

Types of Crystalloid uses in Dengue:

1) 0.9% NaCl (isotonic normal saline solution) (0.9% NS) (Preferable)

2) 0.45% half strength normal saline solution (0.45% NS) (For children <6 months)

3) 5% dextrose in Ringer's lactate solution (5% DRL)

4) 5% dextrose in acetated Ringer's solution (5% DRA)

5) Hartman solution

Types of Colloid uses in Dengue:

- 1) Dextran-based: Dextran 40, Dextran 70
- 2) Starch based (6% HES):
 - Voluven, Plasmasol (6% hydroxyl ethyl ester with normal saline)
 - Volulyte (6% hydroxyl ethyl ester with balanced electrolyte)
- 3) Gelatin
- 4) Human Albumin
- 5) Plasma
- 6) Haemaccel
- 7) Blood and blood components

Indications of Colloid in Dengue

- · Patients with massive plasma leakage
- Patients with shock with rising Hct.
- Those not responding to the maximum volume of crystalloid
- Those with pulse pressure < 10 mm Hg, who need urgent restore BP

Indications for Platelet Concentrate

It has been observed that there is very limited role of platelet transfusion. In most of the situation fresh whole blood transfusion is suffice. However it may be required in some special situation. The indication of which may be as follows:

- 1. Very Severe Thrombocytopania who need urgent surgery
- 2. Clinical judgement of the treating physician

Indications for blood transfusion

- 1. Overt bleeding (more than 10% or 6-8ml/kg)
- 2. Significant drop of Hct. < 40 (<45 for males) after fluid resuscitation
- 3. Hypotensive shock + low/normal Hct.
- 4. Persistent or worsening metabolic acidosis
- 5. Refractory shock after fluid 40-60 ml/kg

Dengue with Organopathy (Expanded Dengue Syndrome): Management Issue

Severe Dengue can be complicated with Myocarditis, Encephalopathy/ Encephalitis/Acute liver failure, AKI, ARDS and sometimes with multiorgan failure (MOF)

- · These complicated patient should be managed by Medicine Specialist/Pediatricians for comprehensive care
- · In myocarditis with raised Troponin I and ECG changes (Bradycardia, Tachycardia, ST-T changes) injudicious use of antiplatelet, anticoagulant or intervention (e.g. pacemaker and others) should be avoided (20% fluid is to be reduced)
- In encephalitis, judicious use of steroids can be given. (Dexamethasone: 0.15 mg / kg 6-8 hourly for 3-5 days)
- In hepatic encephalopathy in dengue, the management should be done as per protocol of Hepatic Encephalopathy
- · For AKI, ARDS or multiorgan failure, appropriate supportive care should be provided

• Hepatic Encephalopathy:

- O2 Therapy
- Fluid: 20% fluid reduction
- Colloid
- Frusemide in fluid overload
- Lactulose
- H2 receptor blocker
- Rifaximin

Monitoring:

(Hepatic Encephalopathy)

- Blood suger
- Correction of electrolytes
- Bleeding episodes
- I/O chart
- Any convulsion

- FFP

Note : Expanded Dengue Syndrome cases should be managed

- In tertiary care setting.
- Here management of EDS is highlighted above.
- For detailed management further reading is recommended

• Pregnancy and Dengue Management:

- Medical termination is to be avoided
- MR should not be allowed
- Hospital delivery advised
- Blood should be available
- Multi-disciplinary approach
- Avoid elective C/S & induction of labour
- No episiotomy
- No instrumental delivery
- In Preterm labour advice delay in delivery
- Injection steroid I/V to be given for Premature delivery
- Active management in third stage of labour
- Misoprostol / Tranexamic acid can be given I/V (1 gm in 10 ml solution administered slowly over 10 minutes)
- All Dengue patients or suspected Dengue patients with pregnancy must get admitted to hospital for close monitoring

• In case of child:

- Shock is to be managed by Normal Saline
- After shock managed, 5% DNS is to used for maintenance
- Below 1 year age: Baby saline (0.45% NaCl) is to be used

PEARLS

No	Do's	Do Not
1	Administration of Paracetamol for high fever and myalgia.	Send patients with non-severe dengue at home without follow-up and inadequate instructions
2	Clinical assessment of the haemodynamic status before and after each fluid bolus	Administer of NSAIDs (eg. Aspirin or Ibuprofen)
3	Give intravenous fluids for repeated vomiting or rapidly rising haematocrit	Miss clinical assessment of patient with respect to fluid therapy
4	Use the appropriate isotonic intravenous fluids for severe dengue in appropriate time and dose	Use intravenous fluids to any patient with mild dengue (those who can take orally)
5	Avoid intramuscular injections	Give intramuscular injections to dengue patients
6	Tight glycaemic control	Avoid monitoring blood glucose
7	Give appropriate Colloid, Packed Red Cell or Fresh Whole Blood if indicated	Give excessive fluid, blood and blood products

National Guideline link:

https://dghs.gov.bd/images/docs/Guideline/NationalGuidelineforDengue2018.pdf

Annexure

Contributors (Not according to Seniority)

Prof. Sameena Chowdhury Prof. Md. Golam Kibria Khan Prof. Neaz T. Parveen Prof. M A Kashem Dr. Sudip Ranjan Deb Dr. Mohammad Abdus Sattar Dr. Amiruzzaman Dr. Durba Halder Dr. Nazim Al-Azad Dr. M M Aktaruzzaman Dr. Motlabur Rahman Dr. Nahida Zafrin Dr. Ashim Chakraborti Dr. Mostofa Kamal Rouf Dr. Abdur Rahim Dr. Syed Ghulam Mogni Mowla Dr. Gobinda Chandra Banik Dr. Fazle Rabbi Chowdhury Dr. Md. Arifuzzaman Dr. Khadiza Sultana Dr. Asim Kumar Saha Dr. Md. Towhidul Hoque Dr. Md. Shafiqul Islam Dr. Md. Mushfigur Rahman Dr. Md. Mosigure Rahman Dr. Anupama Hazarika, MO, CDS, WHO, Bangladesh

Dr. Sabera Sultana, NPO, WHO, Bangladesh





